[The evaluation of the influence of growth hormone therapy on growing process and metabolic functions in patients after treatment of craniopharyngioma].

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

Craniopharyngioma (CP) is a tumor, which damages pituitary function because of its localization.

Panhypopituitarism (PHP) and excessive weight gain with lipid dysfunction are frequently observed.

Who Took Part

According to the abstract, 12 patients were involved.

PubMed indexes the participants as children, both men and women.

12 patients (7 boys and 5 girls) treated for CP with surgery; 3 of them also underwent radiotherapy.

In addition, measurements of TSH, ACTH, LH, FSH.

How the Study Was Run

The mean age at examination time was 11.7 yrs; remission time 2.96 yrs; rGH therapy started on average 3.69 yrs after the surgery.

What Was Measured

Topics PubMed links to this paper include Craniopharyngioma, Growth Disorders, Human Growth Hormone, Overweight, Pituitary Neoplasms and Recombinant Proteins.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Pediatric endocrinology, diabetes, and metabolism), a journal based in Poland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.